drugset

drugset / Trial / NCT00128856

Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

NCT00128856 ↗

Phase 2 Completed 46 enrolled Spanish Breast Cancer Research Group Bristol-Myers Squibb · collab Eli Lilly and Company · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, phase II trial to assess the efficacy of the GAT neoadjuvant regimen in patients with stage III breast cancer.

Timeline

Start: 2003-03
Primary completion: 2015-01
Completion: 2015-01

Publications

Results Sanchez-Rovira P, Anton A, Barnadas A, Velasco A, Lomas M, Rodriguez-Pinilla M, Ramirez JL, Ramirez C, Rios MJ, Castella E, Garcia-Andrade C, San Antonio B, Carrasco E, Palacios JL. Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study. Clin Transl Oncol. 2012 Jun;14(6):430-6. doi: 10.1007/s12094-012-0820-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Doxorubicin	Other / unclassified	40 mg/m2	Intravenous
Subject	Gemcitabine	Small molecule	2000 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	150 mg/m2	Intravenous

Indications